Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168993 · ClinicalTrials.gov registry record · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
A NA study of Lung Cancer (Diagnosis), sponsored by bioAffinity Technologies.
- Recruiting
- Registry status
- NA
- Development phase
- 2,063
- Enrollment target
- 3
- Study locations
NCT07168993: Recruiting NA study of Lung Cancer (Diagnosis), sponsored by bioAffinity Technologies.
NCT07168993 is a NA study of Lung Cancer (Diagnosis) that is actively recruiting participants, run by bioAffinity Technologies. The registered enrollment target is 2,063 participants, below the 4,238-participant average among 6 other Lung Cancer (Diagnosis) trials with a reported enrollment target (51% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168993, a NA study of Lung Cancer (Diagnosis), is actively recruiting participants, sponsored by bioAffinity Technologies.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,063 participants
- Enrollment target
- 3
- Study locations
Study Summary
Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.
Primary Outcome
Evaluate the clinical performance (positive percent agreement \[PPA/sensitivity\] and negative percent agreement \[NPA/specificity\]) of the FlowPath Lung test in predicting lung cancer from the sputum of high-risk individuals with lung nodules
Conditions Studied
Interventions
- OTHER Standard medical treatment
Study Locations (3)
Texas
- Audie Murphy VA Medical Center - San Antonio
- Brooke Army Medical Center - San Antonio
Pennsylvania
- Clinical Research Associates of Central Pennsylvania - DuBois
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,063 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2029-07-01 |
| Phase | NA |
What NCT07168993 shows while recruiting
NCT07168993 is an interventional study that assigns participants to a tested intervention. Its 2,063 participants enrollment target places it among the larger protocols in the corpus, below the 4,238-participant average among 6 other Lung Cancer (Diagnosis) trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Lung Cancer (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which Standard medical treatment is the first listed.
NCT07168993 reports a single indexed study location in Texas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07168993 about?
NCT07168993 is a clinical study titled "Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.". Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.
What is the current status of trial NCT07168993?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,063 participants. The study started on 2026-02-25. Estimated completion is 2029-07-01.
What conditions does trial NCT07168993 study?
This clinical trial studies the following conditions: Lung Cancer (Diagnosis).
What interventions are being tested in trial NCT07168993?
The interventions under investigation include: Standard medical treatment (OTHER).
Who is sponsoring clinical trial NCT07168993?
This trial is sponsored by bioAffinity Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07168993 being conducted?
This trial has 3 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer (Diagnosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
RECRUITING · NA
-
Telehealth Collaborative Care Model (CoCM) in Lung Cancer
RECRUITING · NA
-
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
RECRUITING
-
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RECRUITING
-
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
RECRUITING
-
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
- NCT06521944 · 2,062 participants
RSV Vaccine Pregnancy Registry
- NCT06666192 · 2,067 participants · NA
The Ohio State University (OSU) SCREEN Community Program
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI